MR-Less Surface-Based Amyloid Assessment Based on C-11 PiB PET

Grants

Funding Acknowledgements

Core funding for the AIBL study was provided by the CSIRO (http://www.csiro.au/) Flagship Collaboration Fund and the Science and Industry Endowment Fund (SIEF http://www.sief.org.au/) in partnership with Edith Cowan University (https://www.ecu.edu.au/), Florey neuro-sciences and Mental Health Research institutes (http://www.florey.edu.au/), Alzheimer's Australia (http://www.fightdementia.org.au/), National Age-ing Research Institute (http://www.mednwh.unimelb.edu.au/), Austin Health (http://www.austin.org.au/), CogState Ltd. (http://cogstate.com/), Hollywood Private Hospital (http://www.hollywood.ramsayhealth.com.au/), Sir Charles Gardner Hospital (http://www.scgh.health.wa.gov.au/). The AIBL study also receives funding from the National Health and Medical Research Council (http://www.nhmrc.gov.au/), the Dementia Collaborative Research Centers program (http://www.fightdementia.org.au/victoria/dementia-collaborative-research-centres-1.aspx), The McCusker Alzheimer's Research Foundation (http://alzheimers.com.au/) and Operational Infrastructure Support from the Government of Victoria (http://www.vic.gov.au/), Australia. Pfizer International (http://www.pfizer.com.au/default.aspx) has contributed financial support to AIBL to assist with analysis of blood samples and to further the AIBL research program. The funders had no role in study design and data analysis, decision to publish, or preparation of this manuscript.